Product Description
Mechanisms of Action: Cholesterol Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Amyotrophic Lateral Sclerosis|Muscular Atrophy, Spinal
Phase 2: Non-alcoholic Steatohepatitis|Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Pain Unspecified|Neuropathic Pain|Peripheral Nervous System Diseases|Chemotherapy-induced Peripheral Neuropathy
Phase 1: Healthy Volunteers|Multiple Sclerosis, Relapsing-Remitting|Muscular Atrophy, Spinal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BN29854 | P2 |
Completed |
Muscular Atrophy, Spinal |
2018-12-18 |
30% |
| OLEOS | P3 |
Completed |
Muscular Atrophy, Spinal |
2018-12-18 |
|
| Olesoxime | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
|
| MSREPAIR | P1 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2014-01-01 |